Prosecution Insights
Last updated: November 08, 2026
Application No. 18/470,603

METHODS FOR NEXT GENERATION GENOME WALKING AND RELATED COMPOSITIONS AND KITS

Non-Final OA §103
Filed
Sep 20, 2023
Priority
May 22, 2015 — provisional 62/165,627 +3 more
Examiner
HORLICK, KENNETH R
Art Unit
1681
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Sigma-aldrich Co. LLC
OA Round
1 (Non-Final)
79%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
94%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allowance Rate
832 granted / 1053 resolved
+19.0% vs TC avg
Strong +15% interview lift
Without
With
+15.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
29 currently pending
Career history
1088
Total Applications
across all art units

Statute-Specific Performance

§101
7.9%
-32.1% vs TC avg
§103
28.3%
-11.7% vs TC avg
§102
9.9%
-30.1% vs TC avg
§112
35.0%
-5.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1053 resolved cases

Office Action

§103
Notice of Pre-AIA or AIA Status 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . ELECTION 2. Applicant’s election without traverse of Group III in the reply filed on 07/29/26 is acknowledged. 3. Claims 1-16 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 07/29/26. OBJECTIONS 4. The specification is objected to because of the following informality: the continuation information must be updated to indicate the issue of the parent ‘538 application as US 11,795,501. 5. Claim 21 is objected to because it refers to ‘Table 4’, and claims are usually not permitted to refer to tables and figures in the specification. 2173.05(s) Reference to Figures or Tables Where possible, claims are to be complete in themselves. Incorporation by reference to a specific figure or table “is permitted only in exceptional circumstances where there is no practical way to define the invention in words and where it is more concise to incorporate by reference than duplicating a drawing or table into the claim. Incorporation by reference is a necessity doctrine, not for applicant’s convenience.” Ex parte Fressola, 27 USPQ2d 1608, 1609 (Bd. Pat. App. & Inter. 1993). PRIOR ART REJECTIONS 6. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. 7. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. 8. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. 9. Claims 17-19 and 21 are rejected under 35 U.S.C. 103 as being unpatentable over Pinter et al. (US 2004/0209299). Regarding independent claim 17, Pinter discloses a kit comprising a ligase and a universal adaptor, and methods which also utilize a DNA polymerase. The adaptors comprise a 3’ modification to make the 3’ end non-extendible, and a priming sequence common to all adaptors. See Figs. 1 and 6, and paragraphs 0065-0082, 0101, 0121, 0126, 0204-0205, 0214, 0227-0229, and 0291-0292. Pinter does not explicitly disclose a kit comprising the adaptor, ligase, and a DNA polymerase. One of ordinary skill in the art would have been motivated to modify the kit of Pinter by adding a DNA polymerase because the methods disclosed by Pinter also utilize a DNA polymerase such as Taq, so this would have extended the utility of the kit by including another required reagent. It would have been prima facie obvious to one of ordinary skill in the art at the time the application was filed to make and use the claimed kit. Regarding claim 18, Pinter also discloses the use of a 3’ exonuclease (see paragraph 0075), so it would have been obvious to include this in the kit. Regarding claim 19, Pinter also discloses the use of a universal primer (see paragraph 0214), so it would have been obvious to include this in the kit. Regarding claim 21, selection of particular priming sequences would have merely involved straightforward, logical scientific reasoning or routine optimization of known-important reaction parameters, which as well established in U.S. patent practice does not support unobviousness (M.P.E.P. 2144.05). 10. Claim 20 is rejected under 35 U.S.C. 103 as being unpatentable over Pinter et al. (US 2004/0209299) in view of Drmanac et al. (US 2009/0176234). The teachings of Pinter are discussed above. Pinter does not disclose the use of phosphate as a 3’ blocking moiety on an adaptor. Drmanac discloses the use of phosphate as a 3’ blocking moiety on an adaptor. See paragraph 0184. One of ordinary skill in the art would have been motivated to modify the kit of Pinter by using a 3’-blocked adaptor wherein the modification is a phosphate because Drmanac disclosed the use of such an adaptor. It would have been prima facie obvious to one of ordinary skill in the art at the time the application was filed to make and use the claimed kit. CONCLUSION 11. No claims are free of the prior art. 12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KENNETH R HORLICK whose telephone number is (571)272-0784. The examiner can normally be reached Mon. - Thurs. 8:30 - 6:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Gary Benzion can be reached at 571-272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. 09/23/26 /KENNETH R HORLICK/ Primary Examiner, Art Unit 1681
Read full office action

Prosecution Timeline

Sep 20, 2023
Application Filed
Sep 28, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12781273
PCR DETECTION OF SMALL FRAGMENTS OF A KNOWN NUCLEIC ACID TARGET
3y 3m to grant Granted Nov 03, 2026
Patent 12747466
ANALYSIS OF NUCLEIC ACIDS ASSOCIATED WITH EXTRACELLULAR VESICLES
3y 4m to grant Granted Sep 29, 2026
Patent 12735751
SYSTEMS AND METHODS TO DETECT RARE MUTATIONS AND COPY NUMBER VARIATION
11m to grant Granted Sep 15, 2026
Patent 12729401
CHIMERIC AMPLICON ARRAY SEQUENCING
3y 9m to grant Granted Sep 08, 2026
Patent 12729402
METHODS AND SYSTEMS FOR PROCESSING POLYNUCLEOTIDES
1y 5m to grant Granted Sep 08, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
79%
Grant Probability
94%
With Interview (+15.3%)
2y 5m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1053 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month